|
According to the invention, the method comprises administering of diet to canines, comprising based on the dry weight: DHA+EPA 0.5-2.5%, vitamin C 75-1000 mg/kg, vitamin E 250-1000 mg/kg, L-carnitine 100-1000 mg/kg. The composition of the invention comprises based on the dry weight: DHA+EPA 0.5-2.5%, vitamin C 75-1000 mg/kg, vitamin E 250-1000 mg/kg, L-carnitine 100-1000 mg/kg. |
|
|
Biomarker for alzheimer's disease or mild cognitive impairment Invention relates to the field of medicine, namely to a method of diagnosing Alzheimer's disease or a mild cognitive impairment. The essence of the method consists in the fact than the method includes the measurement of desmosterol, beta-amyloid, and gelsolin in blood. If the desmosterol level in the subject's blood is below the standard value, or if the desmosterol level and Aβx-42 or Aβx-42/Aβx-40 in the subject's blood are below the standard values, or if the desmosterol level and Aβx-42 or Aβx-42/Aβx-40 and the level of helsolin in the subject's blood are below the standard values, Alzheimer's disease or a mild cognitive impairment are diagnosed. |
|
|
Total native DNA is recovered from skin and hair samples; that is followed by carrying out a polymerase chain reaction and amplification of 5.8S rRNA gene fragment of Trichophyton mentagrophytes with using specific primers. If the electrophoresis procedure enables an amplification product of 182 base pairs in size being detected, the agent is considered to be found. |
|
|
Biological material is sampled from the patient by smearing a lateral wall of a vaginal mucosa behind a hymen, and a real-time PRC is conducted to analyse a qualitative and quantitative microbial count and a CD45 gene mRNA expression level. A bacterial inflammatory process in vulva and vagina of girls aged 0 to 8 years is diagnosed if genome equivalents appear to fall within the preset range per a microbial sample, whereas CD45 gene mRNA makes min. 0.5 units in relation to reference genes. |
|
|
Method for determining ccr5 delta 32 allele polymorphism DNA is recovered from cryopreserved umbilical blood. A polymerase chain reaction (PCR) is conducted with using specific primers. The presence of specific DNA fragments is stated after electrophoretic separation of the PCR amplified mixture and ethydium bromide staining. A normal gene version is accompanied by the PCR fragment length making 224 base pairs. In CCR5 delta 32 allele polymorphism, the PCR fragment length is 192 base pairs. |
|
Method for prediction of endometrial receptivity in in vitro fertilisation cycles Determined and measured are an optical expression density of the leukaemia inhibitory factor (LIF) in the germinal and glandular epithelium during an implantation window in the cycle preceding the in vitro fertilisation procedure and the cervical mucus vascular endothelial growth factor (VEGF) on the day of the transvaginal follicular puncture, a systolic-diastolic ratio (S/D) and a spiral artery resistance index (IR) on the day of the trigger shot; that is followed by calculating a regression function (Z) by formula. If Z>0, the endometrium is predicted to be receptive, whereas Z<0 shows the non-receptive endometrium. |
|
|
Multiplex analysis of stacked transgenic protein Invention relates to biotechnology, namely to method of identifying presence of two or more proteins of interest with known amino acid sequences in sample of vegetable origin (versions) and method of preserving genotype of transgenic plant variety. Methods include cleavage of all proteins from sample of vegetable origin with sequence-specific protease with obtaining peptides. Peptides are separated in one step in device for liquid chromatography - mass spectrometry (LC-MS). Peptides are ionised in LC-MS device. Simultaneous obtaining of mass-spectral data for peptides in LC-MS device is performed. Said simultaneous mass-spectral data for peptides with expected mass-spectral data from proteins of interest are compared with known amino acid sequences. Determination of presence or absence of proteins of interest is realised. |
|
Set for detecting spores, originating from mycobacteria Invention relates to the field of microbiology, namely to a set for the detection of spores, originating from mycobacteria in a sample. The set contains an antibody, which specifically binds a spore-related mycobacteria peptide, where the spore-related mycobacteria peptide is selected from the group, consisting of CotA, CotD, CotT, SpoVK, CotSA, YrbC, SpoVE, Soj, SpoIIIE and SEQ ID NO: 2, 4, 6, 8, 10, 12, 16, 18, 20, 22, 24 and 26, where the said antibody is obtained by the immunisation of a human or a non-human organism, with the said peptide, related to the spores. The set additionally contains a molecule, specifically binding a complex between the said antibody and the said spore-related mycobacteria peptide. |
|
Total native DNA is recovered from skin and hair samples; that is followed by carrying out a polymerase chain reaction and amplifying a fragment of 5.8S ribosomal riziform Microsporum canis gene with using specific primers. If the electrophoresis shows an amplification product 182 base pairs in size, the agent is stated to be detected. |
|
|
Invention refers to medicine, particularly oncology and aims at predicting the anti-oestrogen tamoxifen therapy effectiveness. An immune histochemical analysis of a tumour tissue is performed in the patients suffering luminal breast cancer, and a tumour tissue distribution pattern of oestrogen receptors alpha expression is described. Rs2228480 G/A polymorphism is stated in exon 8 of oestrogen receptors alpha (ERα) gene by real-time polymerase chain reaction. The state of regional lymph nodes is assessed. The tumour grade and the anti-oestrogen tamoxifen therapy effectiveness are calculated by formula. If P>0.5, the high anti-oestrogen tamoxifen therapy effectiveness is predicted. P<0.5 shows the low therapy effectiveness and a high probability of progression are predicted. |
|
|
Method for prediction of postpartum osteopenic syndrome Invention refers to medicine. What is presented is a method for the prediction of the postpartum osteopenic syndrome involving studying VDR gene polymorphism Fok-I and predicting the osteopenic syndrome having the genotypes Ff or ff detected. If the genotype FF of the VDR gene polymorphism Fok-I is detected, the VDR gene polymorphism ApaI, BsmI and TaqI are studied additionally. If having at least one of the VDR genotypes AA, Aa ApaI, BB, Bb BsmI and Tt, tt TaqI detected, the postpartum osteopenic syndrome is predicted to develop. |
|
|
Method for evaluating risk of endometrial cancer DNA is recovered from peripheral venous blood which is followed by a genetic typing of the APOE gene and detecting polymorphous alleles APOE*2, APOE*3, APOE*4; if the assays shows any genetic types containing alleles APOE*2, a high risk of endometrial cancer is predicted. |
|
Laboratory method of diagnosing bipolar affective disorder Invention relates to medicine, namely to a method of diagnosing bipolar affective disorder. The essence of the method consists in the fact that reliable differences in the spectrum of protein distribution in blood serum without proteins albumin, immunoglobulin G, immunoglobulin A, antitrypsin, transferin and haploglobin in patients with endogenic psychosis. If protein spots are detected on electrophoretic gel in areas with the molecular weight of 200, 84, 75, 49, 40 kDa in the patient with endogenic psychosis, bipolar affective disorder is diagnosed. |
|
|
Method for determining female serum cytotoxicity to male monoclear cells Method involves determining female serum cytotoxicity to male lymphocytes, including a combined culture with reference male and analysed female serum in a 96-well tray in the presence of the nutrient medium RPMI 1640 in a CO2 incubator. One day later, lymphocytes are counted in the well in a Goryaev's chamber with the male (reference) and female (analysed) serum. That is followed by determining a cytotoxic index (CI), which represents a quotient of the analysed cell count and the reference cell count. The normal cytotoxic index makes approximately 0.7 and less. |
|
|
Method of diagnosing occlusive affection of vessels in patients with cardiovascular diseases Invention relates to the field of medicine and is intended for the diagnostics of an occlusive affection of vessels in patients with cardiovascular diseases. The age, the level of total homocysteine in blood, the presence of C677T polymorphism mutations in the gene of methyletetrahydrofolate reductase, factor V gene G1691A Leiden mutation, 675 4G/5G polymorphism mutations in the gene of the plasminogen activator inhibitor type I are determined in the patient, after which a value of the discriminant function is calculated by formula. In case of D>0, the presence of the occlusive affection of vessels is diagnosed, if D<0, the absence is diagnosed. |
|
|
Method of biochemical identification of highly-toxic anticholinesterase poisons Method includes the determination of an inhibiting impact of a solution of highly-toxic anticholinesterase poison on cholinesterase activity, represented by acetylcholinesterase of human blood erythrocytes, in the presence and in the absence of a substrate, represented by acetylthiocholiniodide. The inhibiting impact of the solution of highly-toxic anticholinesterase poison on the activity of acetylcholinesterase of the human blood erythrocytes is determined first in the presence of the substrate, and then in its absence. An analysed sample is preliminarily diluted by 10 or 100 times to obtain the inhibiting effect on acetylcholinesterase of the human blood erythrocytes in the presence and in the absence of the substrate within 25-75%. After that, the value of the protective effect of acetylthiocholiniodide and the obtained calculated value is compared with table values, determined experimentally in advance for each particular highly-toxic anticholinesterase poison. If the calculated values coincide with the table values, a conclusion about the presence of a respective highly-toxic anticholinesterase poison in the analysed sample is made. |
|
Laboratory diagnostic technique for threatening miscarriage Technique is implemented by biochemical blood analysis followed by determining a diagnostic index by formula: D=X1×K1+X2×K2+X3×K3+X4×K4+const, wherein the values X are described by the biological parameters: X1 is the ceruloplasmin concentration, g/l; X2 is the creatinine concentration, mcmole/l; X3 is the total protein concentration, g/l; X4 is the albumin concentration, g/l; K1, K2, K3; K4 are coefficients: K1=10.4, K2=-0.04, K3=-0.10, K4=0.26, const=-6.84. If D is more than 0, the uncomplicated gestation course is stated with certainty. If D is less than 0, the threatening miscarriage is predicted. |
|
|
Methods and reagents for improvement of detecting amyloid beta-peptides Group of inventions relate to medicine and deals with method of diagnosing neurodegenerative disease in individual, including the following stages (i) determination of one or several parameters, selected from group, consisting of 3ab40 or value of calculated parameter, selected from group, consisting of 2ab40+3ab40, 2ab40+3ab40+2ab42+3ab42 and 1ab40+2ab40+1ab42+2ab42; (ii) comparison of parameter value with standard value, corresponding to value of said parameter in standard sample; and (iii) diagnostics of neurodegenerative disease, in case if increase of parameter value in comparison with standard value is observed. Group of inventions also deals with method of detecting stage, preceding neurodegenerative disease, method of differentiating neurodegenerative disease from stage, preceding said neurodegenerative disease. |
|
Method for predicting acquired myopia in school children Invention refers to medicine, namely to a method for the prediction of acquired myopia in school children. The substance of the method consists in measuring blood haemoglobin concentrations in 6-8-year-old school children to detect haemoglobin deficiency as shown by the difference of an optimum haemoglobin concentration specific for the above age and an actual haemoglobin concentration in a child. If observing no haemoglobin deficiency at the age of 6-8 years old, a low risk of acquired myopia is predicted. The haemoglobin deficiency to 1.7 g/l enables predicting a risk of acquired low myopia. If the haemoglobin deficiency is 1.7 g/l and more, a high risk of progressive myopia to be developed into moderate or high myopia is predicted. |
|
Novel method of diagnosing rheumatoid arthritis and set for rheumatoid arthritis diagnostics Invention relates to method of diagnosing rheumatoid arthritis, method of determining therapeutic agent for treatment of rheumatoid arthritis and set for realisation of methods. Methods are characterised by the fact that include stage of measuring amount of talin in plasma or serum of animal subject. Said measurement is carried out, for instance, by immunologic method with application of antibody, binding with talin. If amount of talin is higher than its average value in control subject without rheumatoid arthritis, rheumatoid arthritis is diagnosed in subject. In case of reduction of talin amount after introduction of therapeutic agent in comparison with amount of talin before introduction, therapeutic effect is stated. Set in accordance with claimed invention contains solid-phase carrier, to which antibody, binding with talin, is attached. |
|
Invention relates to medicine, namely to a method of predicting a probability of reduction of the glomerular filtration rate (GFR) after 3 months of observation after aortocoronary bypass surgery without artificial blood circulation (ACBS without ABC). The essence of the method consists in the fact that the concentration of a kidney injury molecule of type 1 (KIM-1) is determined in blood serum, the ratio of the biomarker KIM-1 concentrations in two time points after 48 hours and 7 days after the operation is calculated and if its value is higher than 1.5, a conclusion about the probability of (GFR) reduction in the remote period after ACBS without ABC is made. |
|
Diagnostic technique for pulmonary thromboembolism based on measuring blood serum interleukin-8 Early diagnostic technique for pulmonary thromboembolism consists in the fact that if the patient shows any clinical signs indicative of the probability of pulmonary thromboembolism, blood serum fibrin D-dimer is supposed to be measured; if the fibrin D-dimer is less than 0.5 mg/l, a suspected case of pulmonary thromboembolism is cleared of, whereat blood serum fibrin D-dimer of 0.5 mg/l and more requires measuring blood serum interleukin-8 additionally by enzyme immunoassay, and if the measured concentration is 21.3 pg/ml and more, pulmonary thromboembolism is diagnosed. |
|
|
Oligopeptide compounds and their applications Invention relates to the field of biotechnology, namely to obtaining oligopeptide compounds, containing a motive, interacting with a proliferating cell nuclear antigen (PCNA) and can be used in medicine. The oligopeptide compound consists of 14-70 amino acids and contains. a PCNA-interacting motive, representing [K/R]-[F/Y/W]-[L/I/V/A]-[L/I/V/A]-[K/R], at least one signal sequence of nuclear localisation and at least one signal sequence of penetration into a cell, with the PCNA-interacting motive being located towards an N-end relative to the signal sequence. |
|
On paramagnetic particles bearing the immobilised bacterial protein G of the family Streptococcus, with the blocked solution Denhardt-DNA the protein BoNT/A is adsorbed using specific highly affinity polyclonal antibodies. The formation of the protein complex BoNT/A is detected with a biotin-conjugated antibody by a noncovalent conjugate of DNA fragments with neutravidin. PCR amplification of the DNA matrix is carried out with the fluorescence detection of the signal in real time. Registration of the presence of BoNT/A in the samples under study is carried out by the change in the level of fluorescence compared to the control ones. |
|
Invention relates to the field of medicine, namely to a method of predicting the development of severe sepsis. The essence of the method consists in the following: on the first day after acute poisoning with substances of narcotic action the content of procalcitonin, interleukin-6 and interleukin-8 is determined in blood serum. If the value of procalcitonin is from 0.5 ng/ml to 5 ng/ml, interleukin-6 from 20 pg/ml to 150 pg/ml, interleukin-8 from 50 pg/ml to 300 pg/ml, the development of severe sepsis is predicted. |
|
Invention relates to the field of molecular genetics, genosystematics and pharmacognosy and is intended for the identification of the species affinity of common heather (Calluna vulgaris (L.) Hull.). Claimed is a set of synthetic oligonucleotides for PCR with the fragment ITS2 of nuclear DNA, including forward and reverse primers and a degradable probe. |
|
Method for detecting benign and malignant new growths of human thyroid Invention aims at detecting benign and malignant new growths in human thyroid. Involved thyroid and reference adjacent intact tissues are sampled; micro-RNA is recovered from the samples; that is followed by conducting a reverse transcription reaction, measuring an expression level of microRNA-21, -221, -222, -155, -205 by real-time RNA followed by a comparative analysis of the microRNA expression according to the norm and thyroid tumour involvement, and stating the presence and type of the new growth. If the above microRNA expression varies by no more than 4 times to the higher and lower figures of expression in relation to the reference, the benign new growth is stated. The malignant new growth is shown by the measured microRNA expression by more than 4 times. |
|
Multimarker panel for left ventricular hypertrophy Present group of inventions refers to medicine, namely to cardiology, and concerns diagnosing various forms of the left ventricular hypertrophy. That is ensured by determining an amount of a necrosis marker - cardiac troponin T, cardiac function marker - NT-proBNP and one of an inflammation marker - GDF-15. Comparing their amounts to the reference values enables diagnosing a physiological or pathological left ventricular hypertrophy. Besides, the presence of the pathological hypertrophy requires determining the relation between the cardiac function marker and inflammatory marker, as well as between the necrosis marker and inflammatory marker, and comparing these relations to the reference enables stating if the individual suffers from hypertrophic nonobstructive cardiomyopathy, or hypertrophic obstructive cardiomyopathy, or hypertrophy accompanying pressure overload. |
|
|
Method of detection of intracellular proteins using fluorescein-5-isothiocyanate (FITC) in various types of mammalian cells is provided, which are characterised by different levels of the synthetic process, using the method of confocal laser microscopy. The mammalian cells are fixed by paraformaldehyde (PFA) preventing the extraction of proteins in subsequent stages of staining, permeabilised with detergent, then stained for 2 h with FITC in a concentration of 1 mcg/ml. The cells are enclosed in Mowiol 4-88 adding DABCO (1,4-diazabicyclo[2.2.2] octane). The resulting preparations are used to analyse the localisation and the content of the protein component of the cells by confocal microscopy. |
|
Method for assessing genetic predisposition to thromboembolia of pulmonary artery If observing clinical risk factors of thromboembolia of the pulmonary artery, venous blood 3 ml is taken from the patient to analyse polymorphisms -174 G>C of IL-6 gene and -308 G>A of TNFalpha gene by polymerase chain reaction. The genetic typing results are determined by assigning certain points: if observing GG genotype of IL-6 gene, 3 points are assigned, GC - 1 point, CC - 0 points; the GG genotype of TNFalpha gene, 3 points are assigned, GA - 1 point, AA - 0 points, the total score of certain patient is derived. If the total score is 4 and more, the presence of individual predisposition to thromboembolia of the pulmonary artery is stated. |
|
|
Observing no development of ventriculomegalia on the 5th day is combined with the postnatal seromucoid concentration of 0.136-0.166 absorbance units measured in supernatant of biological nasopharyngeal aspirate, whereas ventriculomegalia developing on the 5th day is shown by the postnatal seromucoid concentration of seromucoid concentration of 0.167-0.196 absorbance units measured in supernatant of biological nasopharyngeal aspirate. |
|
|
Method of diagnosing clear cell renal cell carcinoma and set for its realisation Claimed group of inventions relates to the field of medicine, in particular to oncology and molecular biology. Claimed are a method and a set of primers and a probe with sequences SEQ ID NO: 1, 2 and 3 for the realisation of a polymerase chain reaction in a real time mode to diagnose clear cell renal cell carcinoma (CCRCC). The quantitative content of mRNA of the NETO2 gene is evaluated. In case of an increased content of mRNA in a supposedly cancer-affected human tissue in comparison with the quantity of mRNA in a healthy tissue, CCRCC is diagnosed. |
|
Method of diagnosing clear cell renal cell carcinoma and set for its realisation Claimed group of inventions relates to the field of medicine, in particular to oncology and molecular biology. Claimed are a method and a set of primers and a probe with sequences SEQ ID NO: 1, 2 and 3 for the realisation of a polymerase chain reaction in a real time mode to diagnose clear cell renal cell carcinoma (CCRCC). The quantitative content of mRNA of the ACY1 gene is evaluated. In case of a reduced content of mRNA in a supposedly cancer-affected human tissue in comparison with the quantity of mRNA in a healthy tissue, CCRCC is diagnosed. |
|
Polymorphism of p53 protein gene is determined in a patient. If observing Arg allele and Arg/Arg genotype of Arg72Pro polymorphous locus of exon 4, the unfavourable course of the disease is predicted. |
|
|
Invention relates to medicine, namely to traumatology and orthopaedics; can be used for the early diagnostics of fat embolism syndrome in case of fractures of long tubular bones and pelvis bones and control of performed treatment efficiency. The method of fat embolism syndrome diagnostics consists in the analysis of serum of venous blood, sampled from a patient on the first day of the post-traumatic period, and determination of the S100B protein concentration in it by enzyme immunoassay. If the protein S100B norm, constituting 125 ng/l, is exceeded, the fat embolism syndrome is diagnosed. |
|
|
Method for prediction of chronic traumatic osteomyelitis accompanying fractures Invention refers to medicine and aims at predicting chronic traumatic osteomyelitis accompanying fractures. The blood is analysed, and if genotype A/A G-308A of TNFa gene is found, chronic traumatic osteomyelitis is predicted. |
|
|
Method for prediction of clinical outcome of congenital pneumonia in small premature infants Cathelicidin LL 37 is measured in a single portion of pharyngeal aspirate on the 1st-2nd day of life. If cathelicidin LL 37 is equal to 10.2 ng/ml or more, the favourable clinical outcome of congenital pneumonia in small premature infants is predicted, while the measured value of less than 10.2 ng/ml shows the lethal outcome. |
|
|
Method for prediction of risk of developing genital prolapse in females Biomaterial is sampled for DNA recovery. That is followed by the DNA genetic typing by tetra-primer allele-specific polymerase chain reaction. The polymorphism of FBLN5 gene in rs12586948 and rs2018736 sites are detected. A high risk of developing genital prolapse is predicted if observing the alleles of nucleotide variants of rs12586948-A and/or rs2018736-C. A lower risk is shown by the alleles of oligonucleotide variants of rs12586948-G and/or rs2018736-A. |
|
Biomarker for patient's monitoring Invention refers to medicine, namely to immune therapy, and can be used to assess the efficacy of treating the patients suffering cancer. That is ensured by administering an immunogenic composition, which contains a recombinant viral vector expressing in vivo the whole MUC-1 antigen or a portion thereof. A method for analysing preparing a biological sample from a patient after the above immunogenic composition has been introduced, and measuring interferon γ in the sample. If interferon γ is more than approximately 4 pg/ml the patient is suggested to show the favourable clinical outcome. |
|
Method is implemented by detecting medium molecular weight peptides in supernatant portion of biological fluid of nasopharyngeal aspirate in the new-borns, wherein the medium molecular weight peptides concentration of 0.785-0.815 optical density units, the absence of ventriculomegalia is diagnosed, while the medium molecular weight peptide concentration of 0.816-0.844 optical density units shows ventriculomegalia. |
|
Invention aims at the prediction of a risk of degree 2-3 placental insufficiency with foetal growth delay syndrome in the pregnant women. Peripheral venous blood is sampled to recover DNA. 20210G/A FII, 1691G/A FV and 10976G/A FVII coagulation factor genes are analysed. Observing 10976G FVII allele and 10976GG FVII genotype enables predicting a high risk of degree 2-3 placental insufficiency with foetal growth delay syndrome in the pregnant women. The presence of combinations of 20210GG FII genotype and 10976A FVII alleles; 20210G FII, 10976A FVII alleles with 1691GG FV genotype or 20210G FII and 10976A FVII alleles provides predicting a low risk of degree 2-3 placental insufficiency with foetal growth delay syndrome in the pregnant women. |
|
Method is implemented by evaluating the relation of GSK-3β/β-actin, calculating a composite score on SIGH-SAD scale. If observing an increase of the relation of GSK-3β/β-actin in blood mononuclear cells of the patients with depressive disorders of more than 0.70, and the total score on SIGH-SAD scale of more than 30, a severe current depressive episode accompanying a recurrent type of depressive disorder is predicted. |
|
Differential diagnostic technique in anaemia in children Invention refers to medicine, namely to haematology, laboratory diagnostics and can be used for the differential diagnostics in anaemia in children. A haematological analyser is used to determine haemogram values and red blood indices, such as: haemoglobin (HB) and reticulocyte haemoglobin (Ret-He), and blood serum is examined for soluble transferring receptor (s-TFR), serum erythropoietin (EPO); the derived values are compared to reference intervals. If the values: HB<120 g/l, s-TFR<25 nIU/ml, Ret>He>29 pg, EPO≤21 mIU/ml, anaemia with underlying inflammation (AI) is stated. If the values: HB<120 g/l, s-TFR>25 nIU/ml, Ret-He<29 pg, EPO>50 mIU/ml, iron deficiency anaemia (IDA) is stated, while the intermediate values falling within the range characterising IDA or AI, the combined IDA or AI are stated. |
|
|
Method for prediction of dysthyroidism Method involves blood serum analyzing for corticotropin-releasing hormone, substance P, neurokinin A and B, interleukin 6 and 8, relaxin and cortisol in females with full-term pregnancy by enzyme immunoassay at the first stage of labour in order to calculate a prognostic probability P by formula: P=(-0.0011229·CRH+(-0.15119·NA)+(-0.0071961·NB)+(-0.021071·IL6)+0.0032637·IL8+(-0.00085785·pF2α)+9.5773·REL+(-0.0098088·SP)+0.0058058·cort)·2.719. If the probability P is more than 0.51, a high risk of dysthyroidism requiring the urgent surgical labour completion is predicted. |
|
|
Diagnostic technique for progressive ovarian carcinoma Invention describes a diagnostic technique for the stages of advanced ovarian carcinoma, involving blood plasma analysis, wherein the patient's disease is staged by the International Federation of Gynaecology and Obstetrics (FIGO) staging system and referred to the clinical stage III or IV as shown by blood plasma protein oxidative modification (POM); stage III is shown by the POM level falling within the range of 4.638 to ∞, while stage IV - by the POM level from 0 to 4.638. |
|
Invention relates to the field of molecular genetics, genetic systematics and pharmacognosy, and is intended for species identification of spiny eleuterococus, eleutherococcus (Eleutherococcus senticocus (Rupr. Et Maxim.) Maxim.). The set of synthetic oligonucleotides for PCR with fragment ITS2 of nuclear DNA is proposed, comprising forward and reverse primers and a destructible probe. |
|
Invention refers to molecular genetics, genetic classification and pharmacognosy and aims at identifying a species of cotton weed (Filaginella uliginosa (L.) Opiz). What is presented is a kit of synthetic oligonucleotides for PCR with ITS2 fragment of a nuclear DNA comprising upstream and downstream primers and a degradable probe. |
|
Invention relates to the field of molecular genetics, genetic systematics and pharmacognosy, and is intended for species identification of Japanese angelica tree (Aralia elata (Miq.) Seem.). The set of synthetic oligonucleotides for PCR with fragment ITS2 of nuclear DNA is proposed, comprising forward and reverse primers and destructible probe. |
|
Method for determining biological age of dead body in recurrent haemorrhage Papillary dermis of the intact skin is examined to determine the expression level of the following immunohistochemical markers per 1 mcm2: elastin, fibrillin, amyloid P, vitronectin, fibulin-5. If the elastin value is less than 11.0%, the fibrillin value is less than 6.0%, the amyloid P value is less than 0.2%, the vitronectin value is less than 0.1%, and the fibulin-5 value is more than 57.0%, the biological age of the dead body is considered to be 5-10 years. If the elastin value is 43.0-64.0%, the fibrillin value is 23.0-47.0%, the amyloid P value is 3.5-7.8%, the vitronectin value is 4.6-6.8%, and the fibulin-5 value is 0.5-4.7%, the biological age of the dead body is considered to be 35-45 years. If the elastin value is less than 3.0%, the fibrillin value is less than 1.5%, the amyloid P value is more than 27.0%, the vitronectin value is more than 12.0%, and the fibulin-5 value is less than 0.1%, the biological age of the dead body is considered to be 70-85 years. |
|
|
Method for determining biological age of dead body in prolonged haemorrhage Determining the biological age of a dead body in prolonged haemorrhage involves measuring the expression level of immunohistochemical markers Ki67, p53 and bcl-2 in the basal epidermis. If the value Ki67 is more than 18.0%, the value p53 is less than 0.3%, the value bcl-2 is more than 12.0%, the biological age of the dead body is considered to be 5-10 years. If the value Ki67 is 7.3-11.6%, the value p53 is 1.0-2.28%, the value bcl-2 is 2.5-7.5%, the biological age of the dead body is considered to be 35-45 years. If the value Ki67 is less than 3.0%, the value p53 is more than 5.5%, the value bcl-2 is less than 0.5%, the biological age of the dead body is considered to be 70-85 years. |
Another patent 2550811.